Nkarta (NKTX) EBITDA Margin (2019)
Nkarta's quarterly EBITDA Margin came in at 692987.01% in Q3 2019, up 430.6% quarter-over-quarter from 209616.77% in Q2 2019.
Nkarta has reported EBITDA Margin for 1 years, with the latest figure at 692987.01% in Q3 2019.
- For the quarter ending Q3 2019, EBITDA Margin changed N/A year-over-year to 692987.01%; the trailing twelve-month figure through Dec 2020 stood at 23728831.17% (changed N/A YoY), and the FY2019 full-year result was 18328.7%, changed N/A from the prior year.
- EBITDA Margin for Q3 2019 stood at 692987.01%, up from 209616.77% in the prior quarter.
- The five-year high for EBITDA Margin was 692987.01% in Q3 2019, with the low at 209616.77% in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 692,987.01% |
| Jun 30, 2019 | -209,616.77% |